CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($) $ in Thousands	Common Stock St. Mary Prescription Pharmacy Class A	Common Stock Capstone Class A	Common Stock Quebec Inc.	Common Stock Class A	Common Stock Class B	Common Stock	Additional Paid-in Capital St. Mary Prescription Pharmacy	Additional Paid-in Capital Capstone	Additional Paid-in Capital Quebec Inc.	Additional Paid-in Capital	Accumulated Deficit	St. Mary Prescription Pharmacy	Capstone	Quebec Inc.	Total
Balance at beginning of period at Dec. 31, 2013											$ (16,020)				$ (16,020)
Balance at beginning of period (in shares) at Dec. 31, 2013				1,799,264	2,108,117
Increase (Decrease) in Stockholders' Equity
Issuance of common stock relating to acquisition							$ 291	$ 374				$ 291	$ 374
Issuance of common stock relating to acquisition (in shares)	81,186	104,822
Accretion (decretion) of redeemable convertible preferred stock										$ (1,009)	(2,875)				(3,884)
Transfer of common stock(in shares)				32,646	(32,646)
Exercise of stock options										59					59
Exercise of stock options (in shares)				41,151
Issuance of common stock warrants										31					31
Stock based compensation expense										254					254
Net income (loss)											(1,107)				(1,107)
Balance at end of period at Dec. 31, 2014											(20,002)				(20,002)
Balance at end of period (in shares) at Dec. 31, 2014				2,059,069	2,075,471
Increase (Decrease) in Stockholders' Equity
Issuance of common stock relating to acquisition							94	$ 107				94	$ 107
Issuance of common stock relating to acquisition (in shares)	16,237	18,418
Accretion (decretion) of redeemable convertible preferred stock										(1,204)	(8,762)				(9,966)
Transfer of common stock(in shares)				4,124	(4,124)
Exercise of stock options										422					422
Exercise of stock options (in shares)				3,132	403,570
Issuance of common stock warrants										16					16
Stock based compensation expense										565					565
Net income (loss)											(2,864)				(2,864)
Balance at end of period at Dec. 31, 2015											(31,628)				(31,628)
Balance at end of period (in shares) at Dec. 31, 2015				2,100,980	2,474,917
Increase (Decrease) in Stockholders' Equity
Issuance of common stock relating to acquisition							$ 35		$ 4,500			$ 35		$ 4,500
Issuance of common stock relating to acquisition (in shares)	10,824		395,407
Accretion (decretion) of redeemable convertible preferred stock										(516)	2,955				2,439
Transfer of common stock(in shares)				2,577	(2,577)
Issuance of common stock (in shares)				1
Issuance of restricted stock (in shares)				722,646
Issuance of common stock upon initial public offering, net of issuance costs										51,226					51,226
Issuance of common stock upon public offering, net of issuance costs (in shares)						4,945,000
Conversion of redeemable convertible preferred stock upon initial public offering						$ 1				26,533					26,534
Conversion of redeemable convertible preferred stock upon initial public offering (in shares)						5,089,436
Redesignation of Class A and Class B common stock upon initial public offering						$ 1									1
Redesignation of Class A and Class B common stock upon initial public offering (in shares)				(2,837,028)	(2,746,377)	5,583,405
Conversion of warrants upon initial public offering										4,930					4,930
Surrender of common stock in connection with Leadership Exit Bonus Plan (in shares)						(20,372)
Issuance of common stock in connection with Leadership Exit Bonus Plan (in shares)						20,372
Shares withheld for tax in connection with Leadership Exit Bonus Plan										(84)					(84)
Shares withheld for tax in connection with Leadership Exit Bonus Plan (in shares)						(7,010)
Net exercise of stock warrants (in shares)					210,817	490,385
Net exercise of stock options (in shares)					63,220	7,052
Exercise of stock options										153					153
Exercise of stock options (in shares)						124,801
Stock based compensation expense										4,250					4,250
Net income (loss)											(6,250)				(6,250)
Balance at end of period at Dec. 31, 2016						$ 2				$ 91,027	$ (34,923)				$ 56,106
Balance at end of period (in shares) at Dec. 31, 2016						16,628,476